Trials / Completed
CompletedNCT00407173
Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects
An Open-Label, Single-Dose, Parallel Group Study to Evaluate the Effects of Age and Gender on the Pharmacokinetics, Safety, and Tolerability of HCV-796 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is an open-label, single-dose, parallel group study to evaluate the effects of age and gender on the pharmacokinetics, safety, and tolerability of HCV-796 administered orally to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCV-796 | HCV-796 1000mg single dose |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-12-04
- Last updated
- 2008-04-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00407173. Inclusion in this directory is not an endorsement.